Mark Cuban’s online pharmacy, Cost Plus Drugs, will soon sell Brenzavvy, an recently FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor for adults with type 2 diabetes.
TheracosBio's Brenzavvy was approved in January. It will compete with the likes of Boehringer Ingelheim/Eli Lilly's Jardiance and AstraZeneca's Farxiga in the SGLT2 inhibitor market — but will distinguish itself with price. While Jardiance sells for $578 and Farxiga for $551 for a 30-day supply, TheracosBio has partnered with Cost Plus to offer Brenzavvy for just $47.85 plus shipping and handling.
In 2021, Mark Cuban, widely recognized for his involvement in "Shark Tank" and ownership of the Dallas Mavericks, introduced his venture into the generic drug market. With a commitment to shaking up the industry, Cuban says his business approach prioritizes "radical transparency" in drug pricing. The company openly discloses its manufacturing, distribution, and marketing costs, while implementing a consistent 15% margin on wholesale prices for all of its drugs.
In a recent statement, Alex Oshmyansky, Cost Plus’ co-founder and CEO shared his enthusiasm for the Brenzavvy offering. “Our main goal is to make as many products as possible available to those who need them at an affordable price. I’m a diabetic myself, so products like Brenzavvy are a top priority,” said Oshmyansky.
